Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.4239
-0.0081 (-1.87%)
At close: Feb 20, 2026, 4:00 PM EST
0.4209
-0.0030 (-0.71%)
After-hours: Feb 20, 2026, 7:35 PM EST
Mereo BioPharma Group Employees
Mereo BioPharma Group had 36 employees as of December 31, 2024. The number of employees increased by 3 or 9.09% compared to the previous year.
Employees
36
Change (1Y)
3
Growth (1Y)
9.09%
Revenue / Employee
$13,889
Profits / Employee
-$1,154,806
Market Cap
67.46M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 36 | 3 | 9.09% |
| Dec 31, 2023 | 33 | -3 | -8.33% |
| Dec 31, 2022 | 36 | -13 | -26.53% |
| Dec 31, 2021 | 49 | 11 | 28.95% |
| Dec 31, 2020 | 38 | -12 | -24.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 152 |
| Fractyl Health | 101 |
| XBiotech | 88 |
| Q32 Bio | 26 |
| Entera Bio | 22 |
| TuHURA Biosciences | 19 |
| Annovis Bio | 15 |
| Instil Bio | 14 |
MREO News
- 3 days ago - Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately - PRNewsWire
- 3 days ago - Stockholders Who Lost Money Investing in Mereo BioPharma Group plc Should Contact Robbins LLP for Information About Recovering Their Losses from MREO - GlobeNewsWire
- 12 days ago - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mereo BioPharma - Newsfile Corp
- 5 weeks ago - Mereo BioPharma Group plc (MREO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - These biotech stocks are getting hammered by shocking brittle-bone treatment study results - Market Watch
- 7 weeks ago - Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta - GlobeNewsWire
- 6 months ago - āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2 - Business Wire
- 6 months ago - Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewsWire